1400635-36-0 Usage
Uses
Used in Pharmaceutical Development:
(5-bromoquinoxalin-6-yl)-(4,5-dihydro-1H-imidazol-2-yl)-amine L-tartrate is used as a potential therapeutic agent for various medical conditions due to its receptor agonist or antagonist activity. (5-bromoquinoxalin-6-yl)-(4,5-dihydro-1H-imidazol-2-yl)-amine L-tartrate's interaction with biological receptors may offer novel treatment options for a range of diseases and disorders.
Used in Drug Discovery Research:
In the field of drug discovery, (5-bromoquinoxalin-6-yl)-(4,5-dihydro-1H-imidazol-2-yl)-amine L-tartrate serves as a valuable compound for studying its effects on different biological systems. Its structural characteristics and potential receptor interactions make it a promising candidate for further exploration in the development of new drugs and therapies.
Used in Chemical Synthesis:
As a derivative of quinoxaline and imidazole, (5-bromoquinoxalin-6-yl)-(4,5-dihydro-1H-imidazol-2-yl)-amine L-tartrate may also be utilized in the synthesis of other complex molecules with potential applications in various industries, including pharmaceuticals, materials science, and chemical research.
Check Digit Verification of cas no
The CAS Registry Mumber 1400635-36-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,0,0,6,3 and 5 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1400635-36:
(9*1)+(8*4)+(7*0)+(6*0)+(5*6)+(4*3)+(3*5)+(2*3)+(1*6)=110
110 % 10 = 0
So 1400635-36-0 is a valid CAS Registry Number.
1400635-36-0Relevant academic research and scientific papers
METHODS OF TREATING OR PREVENTING ACUTE ERYTHEMA
-
, (2011/05/11)
A method of treating or preventing acute erythema in a human in need thereof by topical administration of an effective amount of an alpha adrenergic receptor agonist or pharmaceutically acceptable salt thereof is claimed. The preferred alpha adrenergic re
Brimonidine Compositions for Treating Erythema
-
, (2009/04/24)
The present invention is directed to a pharmaceutical composition including brimonidine tartrate in an amount from about 0.17 percent by weight to about 0.19 percent by weight in a pharmaceutically acceptable carrier such as a gel or cream. The invention
